000143591 001__ 143591
000143591 005__ 20240229112558.0
000143591 0247_ $$2doi$$a10.1002/hep.30493
000143591 0247_ $$2pmid$$apmid:30615206
000143591 0247_ $$2ISSN$$a0270-9139
000143591 0247_ $$2ISSN$$a1527-3350
000143591 0247_ $$2altmetric$$aaltmetric:53705592
000143591 037__ $$aDKFZ-2019-01171
000143591 041__ $$aeng
000143591 082__ $$a610
000143591 1001_ $$aGoeppert, Benjamin$$b0
000143591 245__ $$aIntegrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.
000143591 260__ $$aNew York [u.a.]$$bWiley Interscience$$c2019
000143591 3367_ $$2DRIVER$$aarticle
000143591 3367_ $$2DataCite$$aOutput Types/Journal article
000143591 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681470318_13758
000143591 3367_ $$2BibTeX$$aARTICLE
000143591 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000143591 3367_ $$00$$2EndNote$$aJournal Article
000143591 520__ $$aIntrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver cancer. It is defined by cholangiocytic differentiation and has poor prognosis. Recently, epigenetic processes have been shown to play an important role in cholangiocarcinogenesis. We performed an integrative analysis on 52 iCCAs using both genetic and epigenetic data with a specific focus on DNA methylation components. We found recurrent isocitrate dehydrogenase 1 (IDH1) and IDH2 (28%) gene mutations, recurrent arm-length copy number alterations (CNAs), and focal alterations such as deletion of 3p21 or amplification of 12q15, which affect BRCA1 Associated Protein 1, polybromo 1, and mouse double minute 2 homolog. DNA methylome analysis revealed excessive hypermethylation of iCCA, affecting primarily the bivalent genomic regions marked with both active and repressive histone modifications. Integrative clustering of genetic and epigenetic data identified four iCCA subgroups with prognostic relevance further designated as IDH, high (H), medium (M), and low (L) alteration groups. The IDH group consisted of all samples with IDH1 or IDH2 mutations and showed, together with the H group, a highly disrupted genome, characterized by frequent deletions of chromosome arms 3p and 6q. Both groups showed excessive hypermethylation with distinct patterns. The M group showed intermediate characteristics regarding both genetic and epigenetic marks, whereas the L group exhibited few methylation changes and mutations and a lack of CNAs. Methylation-based latent component analysis of cell-type composition identified differences among these four groups. Prognosis of the H and M groups was significantly worse than that of the L group. Conclusion: Using an integrative genomic and epigenomic analysis approach, we identified four major iCCA subgroups with widespread genomic and epigenomic differences and prognostic implications. Furthermore, our data suggest differences in the cell-of-origin of the iCCA subtypes.
000143591 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000143591 588__ $$aDataset connected to CrossRef, PubMed,
000143591 7001_ $$0P:(DE-He78)cd2ec3f2ae9b2178f113e0f2ed15fc48$$aToth, Reka$$b1$$eFirst author
000143591 7001_ $$aSinger, Stephan$$b2
000143591 7001_ $$aAlbrecht, Thomas$$b3
000143591 7001_ $$0P:(DE-He78)c403a040c97f91902a7d31b93859f9fc$$aLipka, Daniel B$$b4
000143591 7001_ $$0P:(DE-He78)ff1677c63392be9b31a1c8d23db7c9dc$$aLutsik, Pavlo$$b5
000143591 7001_ $$0P:(DE-He78)3860e24c3868c15255c3383a58e8d5b8$$aBrocks, David$$b6
000143591 7001_ $$0P:(DE-HGF)0$$aBaehr, Marion$$b7
000143591 7001_ $$0P:(DE-HGF)0$$aMuecke, Oliver$$b8
000143591 7001_ $$0P:(DE-He78)45a6854ecf41ba2e65ca3ba0d560f14c$$aAssenov, Yassen$$b9
000143591 7001_ $$0P:(DE-HGF)0$$aGu, Lei$$b10
000143591 7001_ $$aEndris, Volker$$b11
000143591 7001_ $$aStenzinger, Albrecht$$b12
000143591 7001_ $$aMehrabi, Arianeb$$b13
000143591 7001_ $$0P:(DE-HGF)0$$aSchirmacher, Peter$$b14
000143591 7001_ $$0P:(DE-He78)4301875630bc997edf491c694ae1f8a9$$aPlass, Christoph$$b15
000143591 7001_ $$0P:(DE-He78)ff4024f7bc236e7897d9c18ee19c451f$$aWeichenhan, Dieter$$b16$$eLast author
000143591 7001_ $$aRoessler, Stephanie$$b17
000143591 773__ $$0PERI:(DE-600)1472120-x$$a10.1002/hep.30493$$gVol. 69, no. 5, p. 2091 - 2106$$n5$$p2091 - 2106$$tHepatology$$v69$$x1527-3350$$y2019
000143591 909CO $$ooai:inrepo02.dkfz.de:143591$$pVDB
000143591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)cd2ec3f2ae9b2178f113e0f2ed15fc48$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000143591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c403a040c97f91902a7d31b93859f9fc$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000143591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ff1677c63392be9b31a1c8d23db7c9dc$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000143591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3860e24c3868c15255c3383a58e8d5b8$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000143591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000143591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000143591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)45a6854ecf41ba2e65ca3ba0d560f14c$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000143591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000143591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000143591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4301875630bc997edf491c694ae1f8a9$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000143591 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ff4024f7bc236e7897d9c18ee19c451f$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000143591 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000143591 9141_ $$y2019
000143591 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000143591 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000143591 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000143591 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000143591 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHEPATOLOGY : 2017
000143591 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000143591 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000143591 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000143591 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000143591 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000143591 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000143591 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000143591 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bHEPATOLOGY : 2017
000143591 9201_ $$0I:(DE-He78)B370-20160331$$kB370$$lEpigenomik$$x0
000143591 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000143591 9201_ $$0I:(DE-He78)C010-20160331$$kC010$$lEpigenomik und Krebsrisikofaktoren$$x2
000143591 980__ $$ajournal
000143591 980__ $$aVDB
000143591 980__ $$aI:(DE-He78)B370-20160331
000143591 980__ $$aI:(DE-He78)L101-20160331
000143591 980__ $$aI:(DE-He78)C010-20160331
000143591 980__ $$aUNRESTRICTED